adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a
Company profile
Ticker
DMK
Exchange
Website
CEO
Dennis Carlo
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Adamis Pharmaceuticals Corp, CELLEGY PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
US Compounding, Inc. • Biosyn, Inc. • Adamis Corporation • Rhombus Pharmaceuticals Corporation ...
IRS number
820429727
DMK stock data
Latest filings (excl ownership)
8-K
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
8 Sep 23
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
1 Sep 23
8-K
Entry into a Material Definitive Agreement
29 Aug 23
8-K
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
21 Aug 23
10-Q
2023 Q2
Quarterly report
18 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
8-K
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
3 Aug 23
424B4
Prospectus supplement with pricing info
3 Aug 23
EFFECT
Notice of effectiveness
2 Aug 23
8-K
Completion of Acquisition or Disposition of Assets
31 Jul 23
Transcripts
DMK
Earnings call transcript
2023 Q1
15 May 23
DMK
Earnings call transcript
2022 Q4
16 Mar 23
DMK
Earnings call transcript
2022 Q3
14 Nov 22
DMK
Earnings call transcript
2022 Q2
11 Aug 22
DMK
Earnings call transcript
2022 Q1
17 May 22
DMK
Earnings call transcript
2021 Q4
31 Mar 22
DMK
Earnings call transcript
2021 Q3
23 Nov 21
DMK
Earnings call transcript
2020 Q3
9 Nov 20
DMK
Earnings call transcript
2020 Q2
20 Aug 20
DMK
Earnings call transcript
2020 Q1
18 May 20
Latest ownership filings
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 670.34 k | 670.34 k | 670.34 k | 670.34 k | 670.34 k | 670.34 k |
| Cash burn (monthly) | 819.86 k | 686.30 k | 3.77 mm | 2.44 mm | 856.18 k | 1.09 mm |
| Cash used (since last report) | 2.31 mm | 1.94 mm | 10.63 mm | 6.88 mm | 2.41 mm | 3.09 mm |
| Cash remaining | -1.64 mm | -1.27 mm | -9.96 mm | -6.21 mm | -1.74 mm | -2.42 mm |
| Runway (months of cash) | -2.0 | -1.8 | -2.6 | -2.5 | -2.0 | -2.2 |
Institutional ownership, Q2 2023
73.8% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 27 |
| Opened positions | 2 |
| Closed positions | 24 |
| Increased positions | 1 |
| Reduced positions | 16 |
| 13F shares | Current |
|---|---|
| Total value | 288.79 mm |
| Total shares | 6.90 mm |
| Total puts | 0.00 |
| Total calls | 38.61 k |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| CVI Investments | 4.92 mm | $2.39 mm |
| Eses Holdings (FZE) | 1.64 mm | $4.33 mm |
| Versi | 177.19 k | $443.00 k |
| BLK Blackrock | 39.53 k | $95.27 mm |
| Vanguard | 30.91 k | $74.49 mm |
| Stonebridge Capital Advisors | 22.00 k | $2.55 mm |
| RVW Wealth | 19.00 k | $2.20 mm |
| Geode Capital Management | 18.95 k | $45.28 mm |
| Cubist Systematic Strategies | 13.66 k | $32.91 mm |
| Harbour Investments | 12.86 k | $1.49 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 15 Sep 23 | Ebrahim Versi | Common Stock | Conversion | Acquire C | Yes | No | 0 | 729,200 | 0.00 | 906,394 |
| 15 Sep 23 | Ebrahim Versi | Series E Convertible Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 729.2 | 0.00 | 1,212 |
| 25 May 23 | Meera J. Desai | Common Stock | Grant | Acquire A | No | No | 0 | 3,138 | 0.00 | 3,138 |
| 25 May 23 | Jannine Versi | Common Stock | Grant | Acquire A | Yes | No | 0 | 177,194 | 0.00 | 177,194 |
| 25 May 23 | Jannine Versi | Series E Convertible Preferred Stock Common Stock | Grant | Acquire A | Yes | No | 0 | 1,941.2 | 0.00 | 1,941.2 |
| 25 May 23 | Jannine Versi | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.9 | 5,144 | 14.92 k | 5,144 |
| 25 May 23 | Jannine Versi | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.9 | 5,144 | 14.92 k | 5,144 |
| 25 May 23 | Jannine Versi | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.9 | 5,144 | 14.92 k | 5,144 |
| 25 May 23 | Jannine Versi | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.9 | 5,144 | 14.92 k | 5,144 |
| 25 May 23 | Jannine Versi | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.9 | 5,144 | 14.92 k | 5,144 |
News
Stocks That Hit 52-Week Lows On Thursday
21 Sep 23
Stocks That Hit 52-Week Lows On Tuesday
19 Sep 23
Stocks That Hit 52-Week Lows On Thursday
7 Sep 23
Adamis Pharmaceuticals Changes Name To DMK Pharmaceuticals To Reflect New Strategic Focus; Company's Common Stock Is Expected To Trade Under The New Nasdaq Ticker Symbol "DMK" On Or About September 8, 2023
7 Sep 23
Stocks That Hit 52-Week Lows On Tuesday
5 Sep 23
Press releases
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
7 Sep 23
Noteworthy Penny Stocks In The News Watchlist (EPAZ, SIRC, ADMP, BLGO)
25 Aug 23
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
21 Aug 23
Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
4 Aug 23
Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
28 Jul 23